J. Staunton

发表

Abstract 2698: eFT226, a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma

P. A. Thompson, K. Webster, N. Young, 2019, Experimental and Molecular Therapeutics.

Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.

P. A. Thompson, C. Stumpf, Qing Han, 2018, Journal of medicinal chemistry.

INT131: a selective modulator of PPAR gamma.

M. Lindstrom, N. Walker, Zhulun Wang, 2009, Journal of Molecular Biology.

Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity

Shunyou Wang, Katrina Chan, C. Rommel, 2009 .

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.

P. A. Thompson, K. Webster, N. Young, 2020, Journal of medicinal chemistry.

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

P. A. Thompson, K. Webster, Katti A. Jessen, 2015 .

Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity

P. A. Thompson, C. Stumpf, K. Webster, 2017 .

Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade

P. A. Thompson, C. Stumpf, K. Webster, 2017 .

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

P. A. Thompson, C. Stumpf, K. Webster, 2021, Frontiers in Oncology.

INT131: A Selective Modulator of PPARγ

M. Lindstrom, N. Walker, Zhulun Wang, 2009 .

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

P. A. Thompson, K. Webster, N. Young, 2020, Molecular Cancer Therapeutics.

Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies

P. A. Thompson, K. Webster, N. Young, 2017 .

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.

Margaret S. Wu, Q. Dang, D. Mackenna, 2017, Journal of medicinal chemistry.

Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer

Shunyou Wang, Katrina Chan, C. Rommel, 2011 .

Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Johannes C. Hermann, R. Neve, R. Everley, 2023, Cancer Research.